Immune Checkpoint Inhibition as a Novel Strategy for Microsatellite Instability-High Duodenal Adenocarcinoma: A Report of Three Cases
Kojiro Shirabe, Tetsuro Kawazoe, Tomoya Harima, Sho Nambara, Yasuo Tsuda, Tomonori Nakanoko, Koji Ando, Eiji Oki, Tomoharu Yoshizumi · 2025
Read Immune Checkpoint Inhibition as a Novel Strategy for Microsatellite Instability-High Duodenal Adenocarcinoma: A Report of Three Cases by Kojiro Shirabe, Tetsuro Kawazoe, Tomoya Harima, Sho Nambara, Yasuo Tsuda, Tomonori Nakanoko, Koji Ando, Eiji Oki, Tomoharu Yoshizumi (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12718700.txt.
Description
Kojiro Shirabe and co-authors report three cases of a rare intestinal cancer treated with immune therapy in this 2025 paper. The cancer grows in the duodenum and makes up under one percent of gut cancers. Most cases surface late, when surgery is hard and outlook poor.
All three tumors carried a DNA repair fault that marks cancers likely to answer immune checkpoint drugs. One patient stayed cancer-free for over five years after surgery and was found to carry a hereditary syndrome. A second, who refused major surgery, kept the disease controlled for nearly two years on the drug alone. A third shrank so fully on the drug that removed tissue showed no live cancer. The authors back the drug as a real option for this group.
Catalog record
| CREATOR | Kojiro Shirabe, Tetsuro Kawazoe, Tomoya Harima, Sho Nambara, Yasuo Tsuda, Tomonori Nakanoko, Koji Ando, Eiji Oki, Tomoharu Yoshizumi |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 19 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |